These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2835696)

  • 1. [Current views on the pathogenesis and pharmacotherapy of Parkinson disease].
    Kostowski W
    Neurol Neurochir Pol; 1987; 21(6):541-7. PubMed ID: 2835696
    [No Abstract]   [Full Text] [Related]  

  • 2. [Dopamine agonists in the therapy of parkinson syndrome].
    Kapfhammer HP; Rüther E
    Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
    [No Abstract]   [Full Text] [Related]  

  • 3. GABA receptor agonists and extrapyramidal motor function: therapeutic implications for Parkinson's disease.
    Bartholini G; Scatton B; Zivkovic B; Lloyd KG
    Adv Neurol; 1987; 45():79-83. PubMed ID: 3030072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
    Hornykiewicz O
    Neurodegener Dis; 2008; 5(3-4):114-7. PubMed ID: 18322366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Search for the cause of Parkinson's disease].
    Langston JW
    Arch Neurobiol (Madr); 1991; 54(6):264-71. PubMed ID: 1811457
    [No Abstract]   [Full Text] [Related]  

  • 6. [Problems and future perspectives in the treatment of Parkinson's disease].
    Hens L; Hellemans J
    Tijdschr Gerontol Geriatr; 1982 Aug; 13(4):147-54. PubMed ID: 6127822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of GABAergic drugs on dopamine catabolism in the nigrostriatal and mesolimbic dopaminergic pathways of the rat.
    Gundlach AL; Beart PM
    J Pharm Pharmacol; 1981 Jan; 33(1):41-3. PubMed ID: 6114152
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
    Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depletion of dopamine in the striatum as an experimental model of Parkinsonism: direct effects and adaptive mechanisms.
    Schultz W
    Prog Neurobiol; 1982; 18(2-3):121-66. PubMed ID: 6813911
    [No Abstract]   [Full Text] [Related]  

  • 10. Parkinson's disease: new approaches to diagnosis and treatment.
    Yahr MD
    Acta Neurol Scand Suppl; 1993; 146():22-5. PubMed ID: 8333251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Abnormal neurotransmission in neurological diseases (author's transl)].
    Toru M
    Tanpakushitsu Kakusan Koso; 1979; 24(2):150-9. PubMed ID: 35816
    [No Abstract]   [Full Text] [Related]  

  • 12. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra.
    Yamamoto BK; Nash JF; Gudelsky GA
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1063-70. PubMed ID: 7791076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current problems of drug treatment of Parkinson disease].
    Kuran W
    Neurol Neurochir Pol; 1980; 14(4):427-35. PubMed ID: 7412998
    [No Abstract]   [Full Text] [Related]  

  • 14. Parkinsonism: candidate disorder for implanted pumps?
    Nutt JG
    Ann N Y Acad Sci; 1988; 531():194-9. PubMed ID: 2898229
    [No Abstract]   [Full Text] [Related]  

  • 15. Dopaminephilic properties of ergot alkaloids.
    Goldstein M; Lew JY; Nakamura S; Battista AF; Lieberman A; Fuxe K
    Fed Proc; 1978 Jun; 37(8):2202-6. PubMed ID: 26607
    [No Abstract]   [Full Text] [Related]  

  • 16. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease.
    Elsworth JD; Roth RH
    Exp Neurol; 1997 Mar; 144(1):4-9. PubMed ID: 9126143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions of dopaminergic and GABAergic neurotransmission: impact of 6-hydroxydopamine lesions into the substantia nigra of rats.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1995 Oct; 275(1):237-44. PubMed ID: 7562556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa in the treatment of Parkinson's disease: current controversies.
    Olanow CW; Agid Y; Mizuno Y; Albanese A; Bonuccelli U; Damier P; De Yebenes J; Gershanik O; Guttman M; Grandas F; Hallett M; Hornykiewicz O; Jenner P; Katzenschlager R; Langston WJ; LeWitt P; Melamed E; Mena MA; Michel PP; Mytilineou C; Obeso JA; Poewe W; Quinn N; Raisman-Vozari R; Rajput AH; Rascol O; Sampaio C; Stocchi F
    Mov Disord; 2004 Sep; 19(9):997-1005. PubMed ID: 15372588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dopamine-receptor stimulants in the treatment of Parkinson's disease (author's transl)].
    Ringwald E; Hirt D; Markstein R; Vigouret JM
    Nervenarzt; 1982 Feb; 53(2):67-71. PubMed ID: 7063089
    [No Abstract]   [Full Text] [Related]  

  • 20. Dopaminergic receptor activity in substantia nigra in the mechanisms of autoregulation of striatal dopamine release.
    Groppetti A; Parenti M; Cattabeni F; Maggi A; De Angelis L; Monduzzi M; Racagni G
    Adv Biochem Psychopharmacol; 1978; 19():363-71. PubMed ID: 696464
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.